Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 1683 • 2014 ACR/ARHP Annual Meeting
Botulinum Toxin-a for the Treatment of Severe Raynaud Phenomenon
Lucía Ruiz Gutiérrez¹, Ana Pérez Gómez¹, Nuria Valdeolivas Casillas², Henry Moruno Cruz¹, Eduardo Cuende Quintana¹, Ana Sánchez Atrio¹, Ana Turrión Nieves¹, Atusa Movasat¹, Cristina Bohórquez Heras¹, Fernando Albarrán Hernández¹, Maria Liz Romero Bogado¹, Susana Medina Montalvo² and Melchor Álvarez de Mon¹, ¹Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, ²Hospital Príncipe de Asturias, Dermatology department, Alcalá de Henares, Madrid, Spain
Background/Purpose Raynaud's phenomenon (RP) is characterized by transient episodes of vasoconstriction of the arteries and arterioles of the extremities in response to cold or emotional…
Abstract Number: 2596 • 2013 ACR/ARHP Annual Meeting
Association Between Nail Fold Capillaroscopy Abnormalities and Thermographic Assessment Of Peripheral Microvascular Dysfunction In An Unselected Cohort Of Patients Under Investigation For Symptoms Of Raynaud’s Phenomenon
Bhavisha Vasta¹, Marina Scolnik^1,2, Darren Hart¹, Jacqueline A. Shipley¹, Sue Brown¹, Eleanor Korendowych¹, Neil J McHugh^1,3 and John D. Pauling^1,3, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Nail fold capillaroscopy (NC) and infrared thermography (IRT) allow objective assessment of digital microvascular abnormalities in patients with Raynaud’s phenomenon (RP) and have an…
Abstract Number: 2597 • 2013 ACR/ARHP Annual Meeting
Acupressure For The Treatment Of Raynaud’s Phenomenon: A Pilot Randomized Controlled Trial
Heather Gladue¹, Richard E. Harris², Veronica Berrocal³, Pei-Suen Tsou⁴, Gautam Edhayan⁵, Ray Ohara⁵ and Dinesh Khanna⁶, ¹University of Michigan, Ann Arbor, MI, ²Anesthesiology, University of Michigan, Ann Arbor, MI, ³Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵University of Michigan Medical School, Ann Arbor, MI, ⁶Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Raynaud’s phenomenon (RP) affects approximately 10% of the US population. The high cost, lack of efficacy, and side effects of conventional medical therapies necessitates…
Abstract Number: 2598 • 2013 ACR/ARHP Annual Meeting
Timing and Outcome Of Transition From Primary To Secondary Raynaud’s Phenomenon: A Capillaroscopic Based Study
Alberto Sulli¹, Giorgia Ferrari², Elena Bernero², Carmen Pizzorni², Vanessa Smith³, Barbara Ruaro² and Maurizio Cutolo⁴, ¹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁴Internal medicine, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy
Background/Purpose: Raynaud's phenomenon (RP) is classified as primary (PRP) or secondary (SRP) depending on its association with an underlying disease (1,2). PRP can evolve to…
Abstract Number: 2179 • 2013 ACR/ARHP Annual Meeting
Consensus: What Agent To Use When First-Line Vasodilatadors Fail In Raynaud´s Phenomenon Or Digital Ulcers Secondary To Juvenile Systemic Sclerosis?
Marìa M. Katsicas¹, Mariana Gonzalez² and Ricardo A. G. Russo³, ¹Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology, Hospital de Pediatría Garrahan, Buenos Aires, Argentina, ³Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina
Background/Purpose: Juvenile Systemic Sclerosis (JSS) is characterized by Raynaud`s phenomenon (RP) and digital ulcers (DU).Conventional therapy includes calcium channel blockers (CCB). A growing number of…
Abstract Number: 1813 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Effect Of Sildenafil On The Microvascular Blood Flow and On The Endothelial Progenitor Cells In Patients With Early Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
Fernando V. Andrigueti, Pâmela C.C. Ebbing, Maria I. Arismendi and Cristiane Kayser, Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Phosphodiesterase-5 inhibitors have been successfully used for the treatment of Raynaud’s phenomenon (RP) in patients with systemic sclerosis (SSc). However, no study has evaluated…
Abstract Number: 853 • 2013 ACR/ARHP Annual Meeting
Capillaroscopy Compared With Color Doppler Ultrasound Of Digital Arteries For Distinguishing Primary From Secondary Raynaud’s Phenomenon
Wolfgang A. Schmidt¹, Katharina Pagel², Bernd Schicke³ and Andreas Krause⁴, ¹Med Ctr Rheumatology Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ²Medical Ctr Rheumatol Berlin Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³Tumorzentrum Berlin, Berlin, Germany, ⁴Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: Raynaud’s phenomenon (RP) is commonly seen in rheumatology practice. Differentiating primary from secondary RP is important for disease management and prognosis. How does capillaroscopy…
Abstract Number: 703 • 2013 ACR/ARHP Annual Meeting
Correlation Between Patient Self-Report Of Symptoms Of Raynaud’s Phenomenon and Objective Assessment Of Digital Microvascular Perfusion Using Infrared Thermography
Marina Scolnik^1,2, Bhavisha Vasta², Darren Hart², Jacqueline A. Shipley², Sue Brown², Eleanor Korendowych², Neil J McHugh^2,3 and John D. Pauling^2,3, ¹Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Patient self-report of digital colour changes form the basis of a clinical diagnosis of Raynaud's phenomenon (RP) and help classify patients with early systemic…
Abstract Number: 704 • 2013 ACR/ARHP Annual Meeting
Evaluating The Effects Of Combination Aspirin and Dipyridamole (asasantin retard) On Platelet Function, Oxidative Stress and Peripheral Vascular Function In Primary Raynaud’s Phenomenon and Systemic Sclerosis
John D. Pauling¹, Jacqueline A. Shipley¹, Darren Hart¹, Ginger L. Milne² and Neil J McHugh^1,3, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: There is evidence of enhanced platelet activation in Raynaud’s phenomenon (RP), particularly in systemic sclerosis (SSc). Upon activation, platelets release vasoconstrictive mediators (e.g. thromboxane…
Abstract Number: 682 • 2013 ACR/ARHP Annual Meeting
Effects Of Extracoporeal Shock Wave Therapy To The Digital Ulcers Of Scleroderma:a Pilot Study
Shinichiro Saito¹, Yukiko Kamogawa², Kyohei Nakamura³, Ryu Watanabe³, Tsuyoshi Shirai², Yoko Fujita⁴, Hiroshi Fujii³, Yuko Shirota⁵, Tomonori Ishii³, Hideo Harigae³, Katsuko Kikuchi⁶ and Yasushi Kawaguchi⁷, ¹Department of hematology and rheumatology, Tohoku University, Sendai, Japan, ²Tohoku University, Sendai, Japan, ³Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁴Department of Hematolgy and rheumatolgy, Tohoku University, Sendai, Japan, ⁵Department of Hematology and Rheumatolgy, Tohoku University, Sendai, Japan, ⁶Department of Dermatology, Tohoku University, Sendai, Japan, ⁷Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Vasculopathy, immunological abnormalities and excessive tissue fibrosis are key elements in the pathogenesis of Scleroderma (SSc). In winter, patients often display Raynaud syndrome, which…
Abstract Number: 1519 • 2012 ACR/ARHP Annual Meeting
Heterogeneous Nuclear RNP-K Is a Novel Cold-Related Autoantigen in Patients with Raynaud’s Phenomenon
Satoshi Serada¹, Minoru Fujimoto² and Tetsuji Naka², ¹Laboratory for immune signal, National Institute of Biomedical Innovation, Laboratory for immune signal, Japan, Ibaraki, Japan, ²Laboratory for immune signal, National Institute of Biomedical Innovation, Ibaraki, Japan
Background/Purpose: Raynaud’s phenomenon (RP) is a vasospastic disorder and shows discoloration of the fingers, toes, and occasionally other areas. RP affects 3-9% of the general…
Abstract Number: 1484 • 2012 ACR/ARHP Annual Meeting
Investigating Determinants of Subjective and Objective Assessments of Peripheral Vascular Function in Primary Raynaud’s Phenomenon and Systemic Sclerosis
John D. Pauling¹, Jacqueline A. Shipley¹, Nigel Harris² and Neil McHugh², ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: The Raynaud’s condition score (RCS) diary is recommended for use in clinical trials of Raynaud’s phenomenon (RP) and systemic sclerosis (SSc). We report the…
Abstract Number: 1495 • 2012 ACR/ARHP Annual Meeting
Platelet Aggregability, Eicosanoid Biosynthesis and Oxidative Stress in Primary Raynaud’s Phenomenon and Systemic Sclerosis
John D. Pauling¹ and Neil McHugh², ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Increased platelet activation, endothelial dysfunction and oxidative stress are all thought to contribute to the pathogenesis of Raynaud’s phenomenon (RP), particularly in the context…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].